Menu
Innovation Observatory > Reports > Drugs > Guadecitabine for Treatment of Naïve Acute Myeloid Leukaemia

< Back

Guadecitabine for Treatment of Naïve Acute Myeloid Leukaemia

Drugs

Cancer and Palliative Care

December 2017


The most common treatment option for AML is chemotherapy to kill the cancerous cells. Guadecitabine is a new treatment being developed for patients who have not received prior treatment (treatment naïve) and are ineligible to undergo intensive chemotherapy. If licenced, guadecitabine would offer a new treatment option for patients that cannot tolerate the standard of care chemotherapy treatments.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Connect to the Innovation Observatory

Twitter

 

Related Information

Guadecitabine for AML



Load More Related Posts
Get Alerts